Header Logo

Connection

Mark Pollack to Animals

Back to Details
This is a "connection" page, showing publications Mark Pollack has written about Animals.
Mark Pollack
Connection Strength
0.340
Animals
  1. Changing times at CNS Neuroscience & Therapeutics. CNS Neurosci Ther. 2008; 14(1):1.
    View in: PubMed
    Score: 0.041
  2. Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14. Infect Immun. 2000 Mar; 68(3):1655-63.
    View in: PubMed
    Score: 0.024
  3. Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime. Microbiol Immunol. 2000; 44(8):629-35.
    View in: PubMed
    Score: 0.023
  4. Dual effects of LPS antibodies on cellular uptake of LPS and LPS-induced proinflammatory functions. J Immunol. 1997 Oct 01; 159(7):3519-30.
    View in: PubMed
    Score: 0.020
  5. Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide. Infect Immun. 1995 Nov; 63(11):4481-8.
    View in: PubMed
    Score: 0.017
  6. Lipopolysaccharide (LPS)-specific monoclonal antibodies regulate LPS uptake and LPS-induced tumor necrosis factor-alpha responses by human monocytes. J Infect Dis. 1995 Sep; 172(3):794-804.
    View in: PubMed
    Score: 0.017
  7. Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06. Infect Immun. 1994 Apr; 62(4):1137-43.
    View in: PubMed
    Score: 0.016
  8. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. J Infect Dis. 1992 Jan; 165(1):34-45.
    View in: PubMed
    Score: 0.013
  9. In vitro and in vivo functional activities of monoclonal antibodies reactive with Pseudomonas aeruginosa serogroup 6 lipopolysaccharides. Antibiot Chemother (1971). 1991; 44:163-71.
    View in: PubMed
    Score: 0.013
  10. Pharmacodynamic and protective properties of a murine lipopolysaccharide-specific monoclonal antibody in experimental Pseudomonas aeruginosa pneumonia in mice. Microbiol Immunol. 1991; 35(12):1131-41.
    View in: PubMed
    Score: 0.013
  11. Specificity and function of monoclonal antibodies reactive with discrete structural elements of bacterial lipopolysaccharide. Adv Exp Med Biol. 1990; 256:331-40.
    View in: PubMed
    Score: 0.012
  12. Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide. Infect Immun. 1989 Feb; 57(2):426-31.
    View in: PubMed
    Score: 0.011
  13. Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide. J Infect Dis. 1989 Feb; 159(2):168-88.
    View in: PubMed
    Score: 0.011
  14. Monoclonal antibodies that recognize epitopes in the core and lipid A region of lipopolysaccharides. Prog Clin Biol Res. 1988; 272:327-38.
    View in: PubMed
    Score: 0.010
  15. Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides. J Clin Invest. 1987 May; 79(5):1421-30.
    View in: PubMed
    Score: 0.010
  16. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev. 2006 Fall-Winter; 12(3-4):208-17.
    View in: PubMed
    Score: 0.009
  17. Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice. Infect Immun. 1984 Feb; 43(2):759-60.
    View in: PubMed
    Score: 0.008
  18. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis. 1983 Jun; 147(6):1090-8.
    View in: PubMed
    Score: 0.007
  19. Toxoid from exotoxin A of Pseudomonas aeruginosa: preparation and characterization. J Infect Dis. 1982 May; 145(5):688-98.
    View in: PubMed
    Score: 0.007
  20. Targeted genome screen of panic disorder and anxiety disorder proneness using homology to murine QTL regions. Am J Med Genet. 2001 Mar 08; 105(2):195-206.
    View in: PubMed
    Score: 0.006
  21. Pseudomonas aeruginosa exotoxin A. N Engl J Med. 1980 Jun 12; 302(24):1360-2.
    View in: PubMed
    Score: 0.006
  22. Mechanism of action of Pseudomonas aeruginosa exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation of elongation factor 2. Infect Immun. 1978 Jan; 19(1):29-33.
    View in: PubMed
    Score: 0.005
  23. Purification of Pseudomonas aeruginosa exotoxin by affinity chromatography. Infect Immun. 1978 Jan; 19(1):66-70.
    View in: PubMed
    Score: 0.005
  24. Serum antibody to Pseudomonas aeruginosa exotoxin measured by a passive hemagglutination assay. J Clin Microbiol. 1977 Jul; 6(1):58-61.
    View in: PubMed
    Score: 0.005
  25. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Invest Ophthalmol Vis Sci. 1997 Jun; 38(7):1418-25.
    View in: PubMed
    Score: 0.005
  26. Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection. Infect Immun. 1976 Oct; 14(4):942-7.
    View in: PubMed
    Score: 0.005
  27. Distinct functional activities in canine septic shock of monoclonal antibodies specific for the O polysaccharide and core regions of Escherichia coli lipopolysaccharide. J Infect Dis. 1994 Mar; 169(3):553-61.
    View in: PubMed
    Score: 0.004
  28. Development of an anti-idiotype monoclonal antibody mimicking the structure of lipopolysaccharide (LPS) inner-core determinants. Microb Pathog. 1993 Aug; 15(2):103-20.
    View in: PubMed
    Score: 0.004
  29. Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother. 1993 Feb; 37(2):164-70.
    View in: PubMed
    Score: 0.004
  30. Lipopolysaccharide (LPS)-reactive monoclonal antibodies fail to inhibit LPS-induced tumor necrosis factor secretion by mouse-derived macrophages. J Infect Dis. 1989 May; 159(5):872-80.
    View in: PubMed
    Score: 0.003
  31. Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide. Infect Immun. 1986 Sep; 53(3):656-62.
    View in: PubMed
    Score: 0.002
  32. Functionally distinct monoclonal antibodies reactive with enzymatically active and binding domains of Pseudomonas aeruginosa toxin A. Infect Immun. 1986 Jun; 52(3):756-62.
    View in: PubMed
    Score: 0.002
  33. Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa. Infect Immun. 1984 Aug; 45(2):309-13.
    View in: PubMed
    Score: 0.002
  34. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections. Infect Immun. 1977 Dec; 18(3):596-602.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.